In Vitro Immunomodulation of a Whole Blood IFN-γ Release Assay Enhances T Cell Responses in Subjects with Latent Tuberculosis Infection

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gaur, Rajiv L ^a   Suhosk, Megan M ^a   Banaei, Niaz ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON; IMIQUIMOD; LIPOPOLYSACCHARIDE; MYCOBACTERIUM TUBERCULOSIS ANTIGEN; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; POLY I-C; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84868136458     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048027     Document Type: Article

References (43)

1. World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response.
2. Comstock GW, Livesay VT, Woolpert SF, (1974) The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 99 (2): 131-138.
3. Vynnycky E, Fine PE, (2000) Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 152 (3): 247-263.
4. Anonymous (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. this official statement of the american thoracic society was adopted by the ATS board of directors, july 1999. this is a joint statement of the american thoracic society (ATS) and the centers for disease control and prevention (CDC). this statement was endorsed by the council of the infectious diseases society of america. (IDSA), september 1999, and the sections of this statement. Am J Respir Crit Care Med 161: S221-47.
5. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr, et al. (2009) Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 106 (33): 13980-13985.
6. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, et al. (1995) The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1 (8): 815-821.
7. von Pirquet C, (1907) Frequency of tuberculosis in childhood. J A M A 52: 675-678.
8. Anonymous (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. american thoracic society. MMWR Recomm Rep 49 (RR-6): 1-51.
9. Herrera V, Perry S, Parsonnet J, Banaei N, (2011) Clinical application and limitations of interferon-γ release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 52 (8): 1031-1037.
10. Menzies D, Pai M, Comstock G, (2007) Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research. Ann Intern Med 146 (5): 340-354.
11. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, et al. (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection- united states, 2010. MMWR Recomm Rep 59 (RR-5): 1-25.
12. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, et al. (2011) The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: A systematic review and meta-analysis. Pediatr Infect Dis J 30 (8): 694-700.
13. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, et al. (2011) Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: A systematic review and meta-analysis. J Acquir Immune Defic Syndr 56 (3): 230-238.
14. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M, (2009) Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: A systematic review. PLoS One 4 (12): e8517.
15. Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, et al. (2011) Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 108 (14): 5730-5735.
16. Ruhwald M, Dominguez J, Latorre I, Losi M, Richeldi L, et al. (2011) A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis 91 (3): 260-267.
17. Mogensen TH, (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22 (2): 240-73.
18. Iwasaki A, Medzhitov R, (2010) Regulation of adaptive immunity by the innate immune system. Science 327 (5963): 291-295.
19. Hoebe K, Janssen EM, Kim SO, Alexopoulou L, Flavell RA, et al. (2003) Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by trif-dependent and trif-independent pathways. Nat Immunol 4 (12): 1223-1229.
20. Honda K, Sakaguchi S, Nakajima C, Watanabe A, Yanai H, et al. (2003) Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A 100 (19): 10872-10877.
21. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, et al. (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2 (10): 947-950.
22. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, et al. (1996) A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335 (26): 1941-1949.
23. Huang SJ, Hijnen D, Murphy GF, Kupper TS, Calarese AW, et al. (2009) Imiquimod enhances IFN-γ production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 129 (11): 2676-2685.
24. Banaiee N, Kincaid EZ, Buchwald U, Jacobs WR Jr, Ernst JD, (2006) Potent inhibition of macrophage responses to IFN-γ by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J Immunol 176 (5): 3019-3027.
25. Doz E, Rose S, Nigou J, Gilleron M, Puzo G, et al. (2007) Acylation determines the toll-like receptor (TLR)-dependent positive versus TLR2-, mannose receptor-, and SIGNR1-independent negative regulation of pro-inflammatory cytokines by mycobacterial lipomannan. J Biol Chem 282 (36): 26014-26025.
26. Gilleron M, Nigou J, Nicolle D, Quesniaux V, Puzo G, (2006) The acylation state of mycobacterial lipomannans modulates innate immunity response through toll-like receptor 2. Chem Biol 13 (1): 39-47.
27. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, et al. (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin mincle. J Exp Med 206 (13): 2879-2888.
28. Coulombe F, Divangahi M, Veyrier F, de Leseleuc L, Gleason JL, et al. (2009) Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 206 (8): 1709-1716.
29. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, et al. (2005) TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 202 (12): 1715-1724.
30. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, et al. (1998) Self-administered topical 5% imiquimod cream for external anogenital warts. HPV study group. human PapillomaVirus. Arch Dermatol 134 (1): 25-30.
31. Coffman RL, Sher A, Seder RA, (2010) Vaccine adjuvants: Putting innate immunity to work. Immunity 33 (4): 492-503.
32. Barrat FJ, Coffman RL, (2008) Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 223: 271-283.
33. Parkinson T, (2008) The future of toll-like receptor therapeutics. Curr Opin Mol Ther 10 (1): 21-31.
34. Iwasaki A, Medzhitov R, (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (10): 987-995.
35. Fritz JH, Le Bourhis L, Sellge G, Magalhaes JG, Fsihi H, et al. (2007) Nod1-mediated innate immune recognition of peptidoglycan contributes to the onset of adaptive immunity. Immunity 26 (4): 445-459.
36. Lahey T, Mitchell BK, Arbeit RD, Sheth S, Matee M, et al. (2011) Polyantigenic interferon-gamma responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One 6 (7): e22074.
37. Kauffman CA, (2007) Histoplasmosis: A clinical and laboratory update. Clin Microbiol Rev 20 (1): 115-132.
38. Pappagianis D, (2001) Serologic studies in coccidioidomycosis. Semin Respir Infect 16 (4): 242-250.
39. Winer S, Chan Y, Paltser G, Truong D, Tsui H, et al. (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15 (8): 921-929.
40. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (7077): 682-687.
41. Vogt G, Nathan C, (2011) In vitro differentiation of human macrophages with enhanced antimycobacterial activity. J Clin Invest 121 (10): 3889-3901.
42. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, et al. (2009) Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119 (5): 1167-1177.
43. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8 (4): 369-377.